{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:06:10Z","timestamp":1787785570476,"version":"build-2784847793"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research was supported by an unrestricted grant by Bristol Myers Squibb."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rheumatoid arthritis (RA) causes bone loss, only partly related to inflammation. The impact of RA treatments on bone metabolism and their ability to mitigate bone loss remains uncertain. The primary goal of our study was to examine the influence of abatacept on serum levels of markers and regulators involved in bone turnover. Secondary objectives included evaluating changes in bone mineral density (BMD), bone health parameters, erosions, and exploring potential correlations among these parameters. We conducted a prospective observational study on patients with active seropositive RA failure to biological disease modifying anti-rheumatic drugs initiating treatment with abatacept. We measured at baseline and after 1, 2, 3, 6, 9 and 12 months: serum bone turnover markers (CTX, P1nP, B-ALP), bone modulators (Dkk-1, sclerostin, vitamin D, PTH, OPG and RANKL), BMD and radiographic parameters (modified Sharp van der Heijde score [mSvdH], bone health index [BHI] and metacarpal index [MCI]). Disease activity and glucocorticoid intake was monitored. 33 patients were enrolled in the study. We found a significant increase in markers of bone formation (B-ALP and P1nP) from baseline to M6 and M12. PTH increased significantly at M6 but not at M12. All other bone markers and modulators did not change. We found a significant decrease in BHI and MCI from baseline to M12 (median difference \u2212\u20090.17 95% CI \u2212\u20090.42 to \u2212\u20090.10, <jats:italic>p<\/jats:italic> 0.001 and \u2212\u20090.09 95% CI \u2212\u20090.23 to \u2212\u20090.07, respectively). BMD at femoral neck transitorily decreased at M6 (mean difference \u2212\u20090.019 g\/cm<jats:sup>2<\/jats:sup> 95% CI \u2212\u20090.036 to \u2212\u20090.001 <jats:italic>p<\/jats:italic> 0.04). BMD at total hip, lumbar spine and mSvdH score did not change significantly. P1nP delta at M12 correlated with delta mSvdH. Treatment with abatacept was associated with a significant increase in bone formation markers. The secondary and transient increase in PTH serum levels may be responsible of the transitory bone loss.<\/jats:p>","DOI":"10.1038\/s41598-023-44374-2","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T11:04:40Z","timestamp":1697022280000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Changes in bone turnover markers and bone modulators during abatacept treatment"],"prefix":"10.1038","volume":"13","author":[{"given":"Giovanni","family":"Adami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Orsolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Pedrollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fratucello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Fassio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Milleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fracassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Bixio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"44374_CR1","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha, D. & Smolen, J. S. Diagnosis and management of rheumatoid arthritis: A review. JAMA 320, 1360\u20131372 (2018).","journal-title":"JAMA"},{"key":"44374_CR2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11926-019-0836-7","volume":"21","author":"G Adami","year":"2019","unstructured":"Adami, G. & Saag, K. G. Osteoporosis pathophysiology, epidemiology, and screening in rheumatoid arthritis. Curr. Rheumatol. Rep. 21, 34 (2019).","journal-title":"Curr. Rheumatol. Rep."},{"key":"44374_CR3","doi-asserted-by":"crossref","first-page":"101611","DOI":"10.1016\/j.beem.2021.101611","volume":"36","author":"G Adami","year":"2021","unstructured":"Adami, G. Regulation of bone mass in inflammatory diseases. Best Pract. Res. Clin. Endocrinol. Metab. 36, 101611 (2021).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"44374_CR4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/BOR.0000000000000608","volume":"31","author":"G Adami","year":"2019","unstructured":"Adami, G. & Saag, K. G. Glucocorticoid-induced osteoporosis update. Curr. Opin. Rheumatol. 31, 388\u2013393 (2019).","journal-title":"Curr. Opin. Rheumatol."},{"key":"44374_CR5","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nm1538","volume":"13","author":"D Diarra","year":"2007","unstructured":"Diarra, D. et al. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med. 13, 156\u2013163 (2007).","journal-title":"Nat. Med."},{"key":"44374_CR6","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.3390\/ijms20235867","volume":"20","author":"G Adami","year":"2019","unstructured":"Adami, G. et al. Osteoporosis in rheumatic diseases. Int. J. Mol. Sci. 20, 5867 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"44374_CR7","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1007\/s10067-017-3734-2","volume":"36","author":"A Fassio","year":"2017","unstructured":"Fassio, A. et al. In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls. Clin. Rheumatol. 36, 2377\u20132381 (2017).","journal-title":"Clin. Rheumatol."},{"key":"44374_CR8","first-page":"77","volume":"33","author":"M Rossini","year":"2015","unstructured":"Rossini, M. et al. In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density. Clin. Exp. Rheumatol. 33, 77\u201383 (2015).","journal-title":"Clin. Exp. Rheumatol."},{"key":"44374_CR9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.intimp.2018.04.019","volume":"59","author":"Y Ma","year":"2018","unstructured":"Ma, Y. et al. The serum level of Dickkopf-1 in patients with rheumatoid arthritis: A systematic review and meta-analysis. Int. Immunopharmacol. 59, 227\u2013232 (2018).","journal-title":"Int. Immunopharmacol."},{"key":"44374_CR10","first-page":"CD007277","volume":"2009","author":"L Maxwell","year":"2009","unstructured":"Maxwell, L. & Singh, J. A. Abatacept for rheumatoid arthritis. Cochrane Database Syst. Rev. 2009, CD007277 (2009).","journal-title":"Cochrane Database Syst. Rev."},{"key":"44374_CR11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00296-017-3922-z","volume":"38","author":"M Tada","year":"2018","unstructured":"Tada, M. et al. Abatacept might increase bone mineral density at femoral neck for patients with rheumatoid arthritis in clinical practice: AIRTIGHT study. Rheumatol. Int. 38, 777\u2013784 (2018).","journal-title":"Rheumatol. Int."},{"key":"44374_CR12","volume":"8","author":"C Wu","year":"2022","unstructured":"Wu, C. et al. Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis. RMD Open 8, e002683 (2022).","journal-title":"RMD Open"},{"key":"44374_CR13","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1136\/ard.2007.080713","volume":"67","author":"R Axmann","year":"2008","unstructured":"Axmann, R. et al. CTLA-4 directly inhibits osteoclast formation. Ann. Rheum. Dis. 67, 1603\u20131609 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"44374_CR14","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/jbmr.3754","volume":"34","author":"H Okada","year":"2019","unstructured":"Okada, H. et al. CTLA4-Ig directly inhibits osteoclastogenesis by interfering with intracellular calcium oscillations in bone marrow macrophages. J. Bone Miner. Res. 34, 1744\u20131752 (2019).","journal-title":"J. Bone Miner. Res."},{"key":"44374_CR15","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/art.38319","volume":"66","author":"S Roser-Page","year":"2014","unstructured":"Roser-Page, S., Vikulina, T., Zayzafoon, M. & Weitzmann, M. N. CTLA-4Ig\u2013induced T Cell anergy promotes Wnt-10b production and bone formation in a mouse model. Arthritis Rheumatol. 66, 990\u2013999 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"44374_CR16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1297-319X(03)00052-6","volume":"70","author":"P Houillier","year":"2003","unstructured":"Houillier, P., Nicolet-Barousse, L., Maruani, G. & Paillard, M. What keeps serum calcium levels stable?. Jt. Bone Spine 70, 407\u2013413 (2003).","journal-title":"Jt. Bone Spine"},{"key":"44374_CR17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2265.1982.tb02760.x","volume":"16","author":"S Adami","year":"1982","unstructured":"Adami, S. et al. Control of secretion of parathyroid hormone in secondary hyperparathyroidism. Clin. Endocrinol. (Oxf.) 16, 463\u2013473 (1982).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"44374_CR18","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1210\/jcem-56-3-572","volume":"56","author":"EM Brown","year":"1983","unstructured":"Brown, E. M. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J. Clin. Endocrinol. Metab. 56, 572\u2013581 (1983).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"44374_CR19","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00223-016-0161-3","volume":"99","author":"G Adami","year":"2016","unstructured":"Adami, G. et al. Effects of TNF inhibitors on parathyroid hormone and Wnt signaling antagonists in rheumatoid arthritis. Calcif. Tissue Int. 99, 360\u2013364 (2016).","journal-title":"Calcif. Tissue Int."},{"key":"44374_CR20","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer, R. M. et al. Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434\u20131441 (2001).","journal-title":"N. Engl. J. Med."},{"key":"44374_CR21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.bone.2017.03.042","volume":"99","author":"R Zebaze","year":"2017","unstructured":"Zebaze, R. et al. Increased cortical porosity is associated with daily, not weekly, administration of equivalent doses of teriparatide. Bone 99, 80\u201384 (2017).","journal-title":"Bone"},{"key":"44374_CR22","volume":"12","author":"H Yamane","year":"2017","unstructured":"Yamane, H. et al. Acute development of cortical porosity and endosteal na\u00efve bone formation from the daily but not weekly short-term administration of PTH in rabbit. PLoS One 12, e0175329 (2017).","journal-title":"PLoS One"},{"issue":"10","key":"44374_CR23","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/jbmr.3209","volume":"32","author":"M Rossini","year":"2017","unstructured":"Rossini, M. et al. Osteoporosis: An independent determinant of bone erosions in rheumatoid arthritis?. J. Bone Miner. Res. 32(10), 2142\u20132143 (2017).","journal-title":"J. Bone Miner. Res."},{"key":"44374_CR24","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/jbmr.2855","volume":"31","author":"R Zebaze","year":"2016","unstructured":"Zebaze, R. et al. Denosumab reduces cortical porosity of the proximal femoral shaft in postmenopausal women with osteoporosis. J. Bone Miner. Res. 31, 1827\u20131834 (2016).","journal-title":"J. Bone Miner. Res."},{"key":"44374_CR25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/art.40385","volume":"70","author":"G Adami","year":"2018","unstructured":"Adami, G. et al. Lack of effect of teriparatide on joint erosions in rheumatoid arthritis is an expected result: Comment on the article by Solomon et al. Arthritis Rheumatol. 70, 475\u2013476 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"44374_CR26","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/art.40156","volume":"69","author":"DH Solomon","year":"2017","unstructured":"Solomon, D. H. et al. Effects of teriparatide on joint erosions in rheumatoid arthritis: A randomized controlled trial. Arthritis Rheumatol. (Hoboken, NJ) 69, 1741\u20131750 (2017).","journal-title":"Arthritis Rheumatol. (Hoboken, NJ)"},{"key":"44374_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210022","author":"M Rossini","year":"2016","unstructured":"Rossini, M., Adami, G., Viapiana, O., Idolazzi, L. & Gatti, D. Denosumab, cortical bone and bone erosions in rheumatoid arthritis. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210022 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"44374_CR28","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/annrheumdis-2018-214827","volume":"78","author":"T Takeuchi","year":"2019","unstructured":"Takeuchi, T. et al. Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): A randomised, double-blind, placebo-controlled phase 3 trial. Ann. Rheum. Dis. 78, 899\u2013907 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"44374_CR29","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s00198-018-4492-y","volume":"29","author":"K Ebina","year":"2018","unstructured":"Ebina, K. et al. Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-na\u00efve rheumatoid arthritis. Osteoporos. Int. 29, 1627\u20131636 (2018).","journal-title":"Osteoporos. Int."},{"key":"44374_CR30","first-page":"1219","volume":"77","author":"Y Matsuura","year":"2018","unstructured":"Matsuura, Y. et al. In vivo visualisation of different modes of action of biological DMARDs inhibiting osteoclastic bone resorption. Ann. Rheum. Dis. 77, 1219\u20131225 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"44374_CR31","doi-asserted-by":"crossref","first-page":"235ra60","DOI":"10.1126\/scitranslmed.3007764","volume":"6","author":"A Bozec","year":"2014","unstructured":"Bozec, A. et al. T cell costimulation molecules CD80\/86 inhibit osteoclast differentiation by inducing the IDO\/tryptophan pathway. Sci. Transl. Med. 6, 235ra60 (2014).","journal-title":"Sci. Transl. Med."},{"key":"44374_CR32","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nrrheum.2014.83","volume":"10","author":"K Ray","year":"2014","unstructured":"Ray, K. Bone: The immune system takes control of bone homeostasis. Nat. Rev. Rheumatol. 10, 382 (2014).","journal-title":"Nat. Rev. Rheumatol."},{"key":"44374_CR33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bone.2007.10.003","volume":"42","author":"S Adami","year":"2008","unstructured":"Adami, S., Viapiana, O., Gatti, D., Idolazzi, L. & Rossini, M. Relationship between serum parathyroid hormone, vitamin D sufficiency, age, and calcium intake. Bone 42, 267\u2013270 (2008).","journal-title":"Bone"},{"key":"44374_CR34","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/14397595.2018.1532622","volume":"29","author":"G Adami","year":"2019","unstructured":"Adami, G. et al. An exploratory study on the role of vitamin D supplementation in improving pain and disease activity in rheumatoid arthritis. Mod. Rheumatol. 29, 1059\u20131062 (2019).","journal-title":"Mod. Rheumatol."},{"key":"44374_CR35","doi-asserted-by":"crossref","first-page":"R216","DOI":"10.1186\/ar3195","volume":"12","author":"M Rossini","year":"2010","unstructured":"Rossini, M. et al. Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability. Arthritis Res. Ther. 12, R216 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"44374_CR36","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nrrheum.2015.140","volume":"12","author":"LE Jeffery","year":"2016","unstructured":"Jeffery, L. E., Raza, K. & Hewison, M. Vitamin D in rheumatoid arthritis-towards clinical application. Nat. Rev. Rheumatol. 12, 201\u2013210 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"44374_CR37","volume":"376","author":"J Hahn","year":"2022","unstructured":"Hahn, J. et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ 376, e066452 (2022).","journal-title":"BMJ"},{"key":"44374_CR38","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00223-013-9749-z","volume":"93","author":"M Rossini","year":"2013","unstructured":"Rossini, M., Gatti, D. & Adami, S. Involvement of WNT\/\u03b2-catenin signaling in the treatment of osteoporosis. Calcif. Tissue Int. 93, 121\u2013132 (2013).","journal-title":"Calcif. Tissue Int."},{"key":"44374_CR39","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1186\/s12891-021-04392-5","volume":"22","author":"S-Y Kawashiri","year":"2021","unstructured":"Kawashiri, S.-Y. et al. Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): A multicenter, prospective, and observational RA ultrasound cohort study in Japan. BMC Musculoskelet. Disord. 22, 506 (2021).","journal-title":"BMC Musculoskelet. Disord."},{"key":"44374_CR40","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2010-2552","volume":"96","author":"D Gatti","year":"2011","unstructured":"Gatti, D. et al. The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J. Clin. Endocrinol. Metab. 96, 1555\u20131559 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"44374_CR41","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s00223-012-9665-7","volume":"92","author":"O Viapiana","year":"2013","unstructured":"Viapiana, O. et al. Sclerostin and DKK1 in primary hyperparathyroidism. Calcif. Tissue Int. 92, 324\u2013329 (2013).","journal-title":"Calcif. Tissue Int."},{"key":"44374_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/art.42529","author":"G Adami","year":"2023","unstructured":"Adami, G. et al. Bone Loss in inflammatory rheumatic musculoskeletal disease patients treated with low-dose glucocorticoids and prevention by anti-osteoporosis medications. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.42529 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"44374_CR43","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00198-019-04906-x","volume":"30","author":"G Adami","year":"2019","unstructured":"Adami, G. & Saag, K. G. Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos. Int. 30, 1145\u20131156 (2019).","journal-title":"Osteoporos. Int."},{"key":"44374_CR44","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00223-019-00649-3","volume":"106","author":"A Fassio","year":"2020","unstructured":"Fassio, A. et al. Acute effects of glucocorticoid treatment, TNF\u03b1 or IL-6R Blockade on bone turnover markers and Wnt inhibitors in early rheumatoid arthritis: A pilot study. Calcif. Tissue Int. 106, 371\u2013377 (2020).","journal-title":"Calcif. Tissue Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44374-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44374-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44374-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T03:24:08Z","timestamp":1700277848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-44374-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["44374"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-44374-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,11]]},"assertion":[{"value":"27 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17183"}}